-
Je něco špatně v tomto záznamu ?
Current use of donor lymphocyte infusions after allogenic stem cell transplantation in Europe: a survey on behalf of the cellular therapy and immunobiology working party of the EBMT
N. Santoro, C. Schmid, M. de Witte, MWH. Roeven, V. Potter, D. Richardson, T. Schroeder, V. Válková, K. Clesham, S. Loron, J. Passweg, C. Besley, B. Gruhn, JD. Hoogenboom, JE. Mooyaart, I. Sanchez-Ortega, S. Pagliuca, F. Simonetta, G....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, multicentrická studie
- MeSH
- alografty MeSH
- dárci tkání MeSH
- homologní transplantace metody MeSH
- lidé MeSH
- nemoc štěpu proti hostiteli MeSH
- průzkumy a dotazníky MeSH
- transfuze lymfocytů * metody MeSH
- transplantace hematopoetických kmenových buněk * metody MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- Geografické názvy
- Evropa MeSH
Unmanipulated donor lymphocyte infusions (DLI) are crucial for enhancing the graft versus tumor (GVT) effect in post-transplant settings. Practices regarding DLI use vary widely among centers, encompassing differences in indications, prerequisites, and application methods. To explore current DLI policies, we developed a comprehensive survey that garnered responses from 165 EBMT centers across 43 countries. Notably, 97% of respondents reported using DLI in their practices. Indications for DLI included preemptive use for minimal residual disease (MRD) positivity in 86.9% of centers and mixed chimerism in 73.1%; therapeutic use for hematological relapse in 73.1%; and prophylactic use for high-risk disease in 43.8%. Active graft-versus-host disease (GVHD) and active infections were deemed absolute contraindications by 85.6% and 57.5% of centers, respectively. 35% of centers did not consider a prior history of acute (a)GVHD as an exclusion criterion. The majority (71.9%) requested immunosuppression withdrawal before DLI. Most centers (71.3%) collected DLI post-transplant, with 78.1% utilizing unstimulated apheresis. The cell doses applied at the first DLI varied significantly, depending on indication, timing, and donor type. This survey provides the largest overview of current DLI practices, highlighting the need for high-quality data to assess the risks and benefits of different approaches.
Centre Hospitalier Lyon Sud Lyon France
Department of Hematology Amsterdam UMC University of Amsterdam Amsterdam The Netherlands
Department of Hematology and Center for Translational Immunology UMC Utrecht Utrecht The Netherlands
Department of Hematology CNRS Nancy University Hospital
Department of Medicine and Clinical Surgery Federico 2 University of Naples Naples Italy
Department of Pediatrics Jena University Hospital Jena Germany
Division of Hematology Department of Oncology Geneva University Hospitals Geneva Switzerland
Division of Hematology Nantes University Hospital
EBMT Leiden Study Unit Leiden The Netherlands
EBMT Medical Officer Executive Office Barcelona Spain
EBMT Statistical Unit Leiden The Netherlands
Hematology Unit Department of Oncology and Hematology Santo Spirito Hospital Pescara Italy
INSERM U1232 CNRS CRCINA Nantes France
Institute of Hematology and Blood Transfusion Prague Czechia
Kings College Hospital London London UK
Radboud University Medical Center Nijmegen Netherlands
San Raffaele Scientific Institute Hematology and Bone Marrow Transplantation Unit Milan Italy
Secretary of the Practice Harmonization and Guidelines Committee of EBMT
Southampton General Hospital Southampton UK
UMR 7365 IMoPA Lorraine University Nancy France
University College London Hospital London UK
University Hospital | Basel Basel Switzerland
University Hospital | Essen Duesseldorf Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015900
- 003
- CZ-PrNML
- 005
- 20250731091336.0
- 007
- ta
- 008
- 250708s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41409-025-02555-9 $2 doi
- 035 __
- $a (PubMed)40123004
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Santoro, Nicole $u Hematology Unit, Department of Oncology and Hematology, Santo Spirito Hospital, Pescara, Italy. nicole.santoro24@gmail.com $1 https://orcid.org/0000000157058084
- 245 10
- $a Current use of donor lymphocyte infusions after allogenic stem cell transplantation in Europe: a survey on behalf of the cellular therapy and immunobiology working party of the EBMT / $c N. Santoro, C. Schmid, M. de Witte, MWH. Roeven, V. Potter, D. Richardson, T. Schroeder, V. Válková, K. Clesham, S. Loron, J. Passweg, C. Besley, B. Gruhn, JD. Hoogenboom, JE. Mooyaart, I. Sanchez-Ortega, S. Pagliuca, F. Simonetta, G. Battipaglia, T. Guillaume, MD. Hazenberg, F. Malard, J. Kuball, A. Ruggeri
- 520 9_
- $a Unmanipulated donor lymphocyte infusions (DLI) are crucial for enhancing the graft versus tumor (GVT) effect in post-transplant settings. Practices regarding DLI use vary widely among centers, encompassing differences in indications, prerequisites, and application methods. To explore current DLI policies, we developed a comprehensive survey that garnered responses from 165 EBMT centers across 43 countries. Notably, 97% of respondents reported using DLI in their practices. Indications for DLI included preemptive use for minimal residual disease (MRD) positivity in 86.9% of centers and mixed chimerism in 73.1%; therapeutic use for hematological relapse in 73.1%; and prophylactic use for high-risk disease in 43.8%. Active graft-versus-host disease (GVHD) and active infections were deemed absolute contraindications by 85.6% and 57.5% of centers, respectively. 35% of centers did not consider a prior history of acute (a)GVHD as an exclusion criterion. The majority (71.9%) requested immunosuppression withdrawal before DLI. Most centers (71.3%) collected DLI post-transplant, with 78.1% utilizing unstimulated apheresis. The cell doses applied at the first DLI varied significantly, depending on indication, timing, and donor type. This survey provides the largest overview of current DLI practices, highlighting the need for high-quality data to assess the risks and benefits of different approaches.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a transfuze lymfocytů $x metody $7 D017710
- 650 12
- $a transplantace hematopoetických kmenových buněk $x metody $7 D018380
- 650 _2
- $a průzkumy a dotazníky $7 D011795
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a homologní transplantace $x metody $7 D014184
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a dárci tkání $7 D014019
- 650 _2
- $a nemoc štěpu proti hostiteli $7 D006086
- 650 _2
- $a alografty $7 D064591
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Schmid, Christoph $u Department of Hematology and Oncology, Augsburg University Hospital and Medical Faculty Comprehensive Cancer Center Augsburg and Bavarian Cancer Research Center, Augsburg, Germany $1 https://orcid.org/000000017070487X
- 700 1_
- $a de Witte, Moniek $u University Medical Centre, Utrecht, The Netherlands $1 https://orcid.org/0000000174702994
- 700 1_
- $a Roeven, Mieke W H $u Radboud University Medical Center, Nijmegen, Netherlands
- 700 1_
- $a Potter, Victoria $u Kings College Hospital London, London, UK
- 700 1_
- $a Richardson, Deborah $u Southampton General Hospital, Southampton, UK $1 https://orcid.org/000000028858923X
- 700 1_
- $a Schroeder, Thomas $u University Hospital | Essen, Duesseldorf, Germany
- 700 1_
- $a Válková, Veronika $u Institute of Hematology and Blood Transfusion, Prague, Czechia
- 700 1_
- $a Clesham, Katherine $u University College London Hospital, London, UK
- 700 1_
- $a Loron, Sandrine $u Centre Hospitalier Lyon Sud, Lyon, France
- 700 1_
- $a Passweg, Jakob $u University Hospital | Basel, Basel, Switzerland $1 https://orcid.org/0000000170923351
- 700 1_
- $a Besley, Caroline $u University Hospitals Bristol and Weston NHSFT, Bristol, UK
- 700 1_
- $a Gruhn, Bernd $u Department of Pediatrics, Jena University Hospital, Jena, Germany $1 https://orcid.org/0000000318620075
- 700 1_
- $a Hoogenboom, Jorinde D $u EBMT Leiden Study Unit, Leiden, The Netherlands
- 700 1_
- $a Mooyaart, Jarl E $u EBMT Statistical Unit, Leiden, The Netherlands
- 700 1_
- $a Sanchez-Ortega, Isabel $u Secretary of the Practice Harmonization and Guidelines Committee of EBMT; EBMT Medical Officer, Executive Office, Barcelona, Spain $1 https://orcid.org/0009000555199154
- 700 1_
- $a Pagliuca, Simona $u Department of Hematology, CNRS, Nancy University Hospital; UMR 7365, IMoPA, Lorraine University, Nancy, France
- 700 1_
- $a Simonetta, Federico $u Division of Hematology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland
- 700 1_
- $a Battipaglia, Giorgia $u Department of Medicine and Clinical Surgery, Federico II University of Naples, Naples, Italy $1 https://orcid.org/0000000206953879
- 700 1_
- $a Guillaume, Thierry $u Division of Hematology, Nantes University Hospital; INSERM U1232 CNRS, CRCINA, Nantes, France $1 https://orcid.org/0000000154828565
- 700 1_
- $a Hazenberg, Mette D $u Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
- 700 1_
- $a Malard, Florent $u Sorbonne Université, Centre de Recherche Saint-Antoine INSERM UMRs938, Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France $1 https://orcid.org/0000000234740002
- 700 1_
- $a Kuball, Jürgen $u Department of Hematology and Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands $1 https://orcid.org/0000000239147806
- 700 1_
- $a Ruggeri, Annalisa $u San Raffaele Scientific Institute, Hematology and Bone Marrow Transplantation Unit, Milan, Italy $1 https://orcid.org/0000000272612765
- 773 0_
- $w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 60, č. 5 (2025), s. 697-701
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40123004 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091331 $b ABA008
- 999 __
- $a ok $b bmc $g 2366618 $s 1253025
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 60 $c 5 $d 697-701 $e 20250323 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
- LZP __
- $a Pubmed-20250708
